multitarget antiangiogenic agents  (MultiTarget Pharmaceuticals)

Journal: Theranostics

Article Title: Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapy

doi: 10.7150/thno.89306

Figure Lengend Snippet: Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical bevacizumab (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.

Article Snippet: The clinically used antiangiogenic agent bevacizumab (MedChemExpress, NJ, USA, #HY-P9906) was diluted in phosphate-buffered saline (PBS, pH 7.4, Hyclone, USA), and was administered every other day for 12 days ( ) via intraperitoneal injection at a dose of 10 mg/kg for animals in the treatment group.

Techniques: Functional Assay, Derivative Assay

Journal: Scientific Reports

Article Title: Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents

doi: 10.1038/s41598-026-37059-z

Figure Lengend Snippet: Effect of nicorandil (Nic) and aflibercept (Afl) on blood pressure. ( a ) Systolic (SBP), ( b ) diastolic (DBP), and ( c ) mean arterial pressure (MBP). Ctrl: control group, Afl: aflibercept group (10 mg/kg twice a week subcutaneously), Nic: nicorandil group (10 mg/kg/day via drinking water), and Com: combination group (aflibercept [10 mg/kg twice a week] + nicorandil [10 mg/kg/day via drinking water]). n = 6 in each group, *indicates p < 0.05 according to two-way analysis of variance (ANOVA) test.

Article Snippet: The antiangiogenic agent aflibercept (ZALTRAP IV infusion) was purchased from Sanofi K. K. (Tokyo, Japan).

Techniques: Control

Journal: Scientific Reports

Article Title: Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents

doi: 10.1038/s41598-026-37059-z

Figure Lengend Snippet: ( a ) Comparison of tumor volume (mm 3 ) between the four treatment groups. Ctrl: control group, Afl: aflibercept group (10 mg/kg twice a week subcutaneously), Nic: nicorandil group (10 mg/kg/day via drinking water), and Com: combination group (aflibercept [10 mg/kg twice a week] + nicorandil [10 mg/kg/day via drinking water]). n = 4–6 in each group, *indicates p < 0.05 according to two-way analysis of variance (ANOVA) test. ( b ) In vivo imaging analysis of tumor bearing mice. Luminescent images derived from MDA-MB-231-Luc cells subcutaneously transplanted in the back of the nude-mice was taken from the IVIS system. Pictures were taken 35 days after drug treatment initiation.

Article Snippet: The antiangiogenic agent aflibercept (ZALTRAP IV infusion) was purchased from Sanofi K. K. (Tokyo, Japan).

Techniques: Comparison, Control, In Vivo Imaging, Derivative Assay